PD-1 and CTLA-4 inhibition are subject of extended clinical studies and led already to impressive response rates in some tumor entities, among them melanoma, non–small cell lung cancer and for hematopoietic tumors, (184–186), in cHL as well (187, 188). Here, PDCD1 is linked to neoplasm.